Abstract:SCN–VAN connectivity may be an antidepressant target associated with depressive state changes and a predictor of treatment response to serotonin reuptake inhibitors. The within‐network hypoconnectivity in SCN and DMN may reflect a trait‐like abnormality in MDD. Lack of placebo control is a limitation of this study. In this study, the effects of antidepressants on large‐scale brain networks and the neural basis of individual differences in response were explored. A total of 41 patients with major depressive disorder (MDD) and 42 matched healthy controls (HCs) were scanned by resting‐state functional magnetic resonance imaging separately at baseline and after a 12‐week follow‐up. The patients with MDD received escitalopram for 12 weeks. After treatment, patients were classified into those with MDD in remission [MDDr, endpoint 17‐item Hamilton Depression Rating Scale (HAMD) total score ≤7] and those in nonremission (MDDnr). The human Brainnetome Atlas was used to define large‐scale networks and compute within‐ and between‐network resting‐state functional connectivity (rsFC). Results showed the decreased subcortical network (SCN)–ventral attention network (VAN) connectivity at baseline increased in patients with MDD after 12‐week treatment, and it was comparable with that of HCs. This change was only observed in patients with MDDr. However, the decreased within‐network rsFC in SCN and default mode network (DMN) persisted in all patients with MDD, including those with MDDr and MDDnr, after treatment. The strength of SCN–VAN connectivity at baseline was significantly negatively correlated with the reduction rate of HAMD score in all patients with MDD. Thus, SCN–VAN connectivity may be an antidepressant target associated with depressive state changes and a predictor of treatment response to serotonin reuptake inhibitors. The within‐network rsFC in SCN and DMN may reflect a trait‐like abnormality in MDD. These findings provide further insights into the mechanism of antidepressants and their individual differences in response. The trial name is "Appropriate technology study of MDD diagnosis and treatment based on objective indicators and measurement" (URL: http://www.chictr.org.cn/showproj.aspx?proj=21377; registration number: ChiCTR‐OOC‐17012566).

Effect of short-term escitalopram treatment on neural activation during emotional processing

Amygdala activity after subchronic escitalopram administration in healthy volunteers: A pharmaco-functional magnetic resonance imaging study

Functional brain responses to emotional faces after three to five weeks of intake of escitalopram in healthy individuals: a double-blind, placebo-controlled randomised study

Early changes in emotional processing as a marker of clinical response to SSRI treatment in depression

Short-term Effects of Escitalopram on Regional Brain Function in First-Episode Drug-Naive Patients with Major Depressive Disorder Assessed by Resting-State Functional Magnetic Resonance Imaging

Dissociable Effects of Acute SSRI (escitalopram) on Executive, Learning and Emotional Functions in Healthy Humans.

Acute SSRI Administration Affects the Processing of Social Cues in Healthy Volunteers

Effects of escitalopram on synaptic density in the healthy human brain: a randomized controlled trial

Mapping the effect of escitalopram treatment on amplitude of low-frequency fluctuations in patients with depression: a resting-state fMRI study

Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model

Allelic Variation in 5-HTTLPR and the Effects of Citalopram on the Emotional Neural Network.

Differential Effects of Antidepressant Treatment on Long-Range and Short-Range Functional Connectivity Strength in Patients with Major Depressive Disorder

Chronic Escitalopram in Healthy Volunteers Has Specific Effects on Reinforcement Sensitivity: a Double-Blind, Placebo-Controlled Semi-Randomised Study

Effect of acute citalopram on self-referential emotional processing and social cognition in healthy volunteers

Effects of escitalopram therapy on effective connectivity among core brain networks in major depressive disorder

Effects of 12‐week escitalopram treatment on resting‐state functional connectivity of large‐scale brain networks in major depressive disorder

Escitalopram modulates learning content-specific neuroplasticity of functional brain networks

Central serotonin modulates neural responses to virtual violent actions in emotion regulation networks

Resting state functional connectivity patterns as biomarkers of treatment response to escitalopram in patients with major depressive disorder

Predicting Escitalopram Monotherapy Response in Depression: the Role of Anterior Cingulate Cortex

Escitalopram Targets Oxidative Stress, Caspase-3, BDNF and MeCP2 in the Hippocampus and Frontal Cortex of a Rat Model of Depression Induced by Chronic Unpredictable Mild Stress